Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
Poster Presentation to Spotlight Ongoing Phase 1 Clinical Trial of EVOLVE104 Oral and Poster Presentations to Highlight Preclinical Data Demonstrating Ability of EVOLVE Platform to Drive Enhanced T...
-
STAFFORD, Texas, April 14, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial,...
-
SOUTH SAN FRANCISCO, Calif., April 13, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO) today announced that it intends to offer and sell, in an underwritten public offering and...
-
LOS ANGELES, April 02, 2026 (GLOBE NEWSWIRE) -- via IBN -- Oncotelic Therapeutics, Inc. (“Oncotelic” or the “Company”), a clinical-stage biotechnology company focused on oncology and AI-driven...
-
SAN DIEGO, April 02, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a biotechnology company pioneering the development of targeted genetic...
-
NEW YORK, April 01, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural killer T (allo-iNKT) cell...
-
Dublin, March 30, 2026 (GLOBE NEWSWIRE) -- The "Paraganglioma Market Report 2026" has been added to ResearchAndMarkets.com's offering.The paraganglioma market is on an upward trajectory, with...
-
Siren Biotechnology Announces FDA Clearance of Investigator-Initiated IND to Advance Phase 1 Study in Recurrent High-Grade Glioma
-
STAFFORD, Texas, March 19, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial,...
-
STAFFORD, Texas, March 18, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial,...